Drugs Containing Excipient (Inactive Ingredient) PHENOL

Branded drugs containing PHENOL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novo Nordisk	SAXENDA	liraglutide	0169-2800	PHENOL	1969-12-31
Novo Nordisk	VICTOZA	liraglutide	0169-4060	PHENOL	1969-12-31
Novo Nordisk	OZEMPIC	semaglutide	0169-4136	PHENOL	2028-01-28
Par Pharmaceutical Inc	TIGAN	trimethobenzamide hydrochloride	42023-118	PHENOL
A-S Medication Solutions	HUMULIN	insulin human	50090-0352	PHENOL
A-S Medication Solutions	NOVOLIN	human insulin	50090-0403	PHENOL

Generic drugs containing PHENOL excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	insulin lispro	0002-7510	PHENOL
Eli Lilly and Company	insulin lispro	0002-7511	PHENOL
Eli Lilly and Company	insulin lispro	0002-7512	PHENOL
Eli Lilly and Company	insulin lispro	0002-8233	PHENOL
Eli Lilly and Company	insulin human	0002-8315	PHENOL
Eli Lilly and Company	insulin human	0002-8715	PHENOL

# Phenol Pharmaceutical Excipient Market Dynamics, Patent Position, Regulatory Status, and Financial Outlook

Last updated: August 14, 2026

Phenol is a mature, low-cost pharmaceutical excipient used mainly as an antimicrobial preservative in multidose injectable products, vaccines, insulin formulations, and selected topical medicines. Its commercial value is driven less by pharmaceutical demand than by the broader phenol chain, particularly bisphenol A, phenolic resins, caprolactam, and acetone production. Pharmaceutical-grade phenol has limited standalone market transparency, but demand is relatively stable because it is embedded in approved product formulations and supported by established pharmacopeial standards.

The main risks are toxicological scrutiny, substitution by m-cresol or alternative preservatives, declining use of multidose presentations, and customer qualification requirements. The patent risk for phenol itself is low. The relevant intellectual-property risk sits in drug-specific formulations, preservative systems, delivery devices, and manufacturing processes.

What is phenol used for in pharmaceutical formulations?

Phenol, CAS No. 108-95-2, is used primarily as a preservative and antimicrobial excipient. It is a small aromatic compound with established chemical, pharmacological, and toxicological profiles.

Pharmaceutical use	Typical product category	Commercial relevance
Antimicrobial preservative	Multidose injectable drugs	Core pharmaceutical use
Preservative	Insulin and other peptide products	Important but formulation-specific
Preservative	Vaccines supplied in multidose formats	Stable demand where permitted
Antiseptic or local anesthetic component	Selected topical and otic products	Smaller and more regulated segment
Manufacturing or processing use	Selected pharmaceutical processes	Not always present in final dosage form

Phenol is not the same substance as phenol red, which is a separate pH indicator used in some biological media and formulations.

The excipient is normally selected to control microbial growth after repeated vial access. Its value comes from formulation performance, historical regulatory acceptance, and compatibility with the active ingredient and container closure system.

Which pharmaceutical products contain phenol?

Approved product labels identify phenol in several injectable and vaccine formulations. Examples include some insulin products and pneumococcal or typhoid vaccine presentations.

Insulin formulations

Phenol and m-cresol are used separately or together in insulin products. The preservative system can affect:

• Antimicrobial protection after vial entry
• Protein aggregation and fibrillation
• Local injection-site tolerability
• Container compatibility
• Stability during refrigerated storage and in-use periods

Humalog and NovoLog labeling identifies phenol or related cresol preservatives in specific presentations. The exact composition varies by product, concentration, and dosage form. Manufacturers cannot generally substitute preservatives without new formulation, stability, extractables and leachables, and regulatory work.

Vaccines

Phenol is present in certain multidose vaccine formulations, including products such as Pneumovax 23 and Typhim Vi, according to U.S. labeling. Single-dose and preservative-free presentations reduce the need for phenol, but they also increase packaging and administration costs.

Topical and local-use products

Phenol has a long history in topical antiseptic, throat, dermatological, and local anesthetic products. Its use is more constrained than in industrial applications because of systemic toxicity, corrosivity, and occupational exposure concerns.

What is the FDA regulatory status of phenol as an excipient?

Phenol is an established pharmaceutical ingredient, but FDA acceptance depends on route, dosage form, concentration, and the specific drug product. The FDA Inactive Ingredient Database records excipient use by dosage form and route; inclusion does not constitute universal approval for every product or concentration (U.S. Food and Drug Administration, n.d.-a).

The regulatory position has four practical components:

1. Inactive ingredient precedent. Existing FDA-approved products establish route- and formulation-specific precedent.
2. Pharmacopeial quality. Pharmaceutical-grade material is generally controlled against applicable USP-NF, Ph. Eur., or other recognized monographs.
3. Product-specific approval. A new drug using phenol must establish safety, identity, strength, quality, and suitability in the proposed formulation.
4. Exposure control. Toxicology, residual levels, container compatibility, and administration frequency influence regulatory review.

Phenol is not automatically acceptable in every parenteral, pediatric, ophthalmic, or biologic formulation. The intended route and exposure level remain decisive.

What quality attributes matter for pharmaceutical-grade phenol?

Key quality attributes include:

• Assay and related substances
• Water content
• Appearance and color
• Residual solvents
• Heavy metals or elemental impurities
• Oxidation products
• Microbial quality where applicable
• Packaging and storage controls
• Batch-to-batch consistency

Phenol can oxidize or discolor under unfavorable storage conditions. Pharmaceutical buyers therefore require controlled handling, suitable packaging, validated transport, and a complete certificate-of-analysis package.

How large is the pharmaceutical phenol market?

Public financial reporting does not usually separate pharmaceutical-grade phenol from the much larger industrial phenol market. That makes standalone market-size estimates less reliable than estimates for the overall phenol industry.

The global phenol market is dominated by applications outside pharmaceuticals:

• Bisphenol A for polycarbonate and epoxy resins
• Phenolic resins
• Caprolactam and nylon intermediates
• Alkylphenols and specialty chemicals
• Solvents and chemical intermediates

Pharmaceutical excipient demand is a small niche within this broader chain. Its economics are determined by qualification, purity, supply continuity, and regulatory documentation rather than by bulk volume.

What drives pharmaceutical phenol demand?

Demand is supported by:

• Continued use of multidose injectable products
• Legacy insulin formulations
• Multidose vaccine presentations
• Established supplier qualification
• Low formulation cost relative to higher-priced alternatives
• Long product lifecycles for approved medicines

Demand is constrained by:

• Growth in single-dose and preservative-free packaging
• Substitution with m-cresol or other preservative systems
• Toxicity and handling requirements
• Reduced use in pediatric and sensitive patient populations
• Biologic formulation trends that favor lower-excipient complexity
• Customer concentration among a limited number of global drug manufacturers

The pharmaceutical segment is therefore defensive but not a high-growth market.

How does the phenol supply chain affect pharmaceutical pricing?

Phenol is primarily manufactured through the cumene process, which produces phenol and acetone. This links phenol economics to both crude-oil-derived feedstocks and downstream acetone demand.

Major cost drivers

Cost factor	Effect on pharmaceutical phenol
Benzene and propylene prices	Determines cumene-feedstock economics
Acetone demand	Affects integrated producer operating economics
Energy and utilities	Influences production and purification cost
Plant outages	Can cause regional supply tightness
Freight and hazardous-material controls	Raises delivered cost
Pharmaceutical-grade purification	Creates a premium over industrial grades
Regulatory documentation	Increases qualification and compliance costs

The pharmaceutical premium is usually more important than the underlying chemical price. A drug manufacturer may pay more for a qualified supplier because switching requires formulation assessment, stability work, quality audits, and regulatory submissions.

Which companies supply phenol to pharmaceutical manufacturers?

The upstream market includes large integrated phenol producers such as INEOS Phenol, Mitsui Chemicals, Kumho P&B Chemicals, SABIC, and Cepsa, although product availability and pharmaceutical-grade qualification vary by region and grade.

Laboratory and pharmaceutical distribution channels include companies such as Merck, Avantor, Thermo Fisher Scientific, and specialized regional distributors. These companies may distribute phenol rather than manufacture the underlying molecule.

The relevant competitive distinction is between:

• Bulk phenol producers
• Pharmaceutical-grade refiners
• Catalog and laboratory suppliers
• Regional distributors
• Contract manufacturers with validated excipient supply chains

A catalog listing does not establish that the material is qualified for a commercial injectable product.

What patents protect phenol as a pharmaceutical excipient?

No meaningful blocking patent estate appears to protect phenol as a basic pharmaceutical excipient. Phenol is an old, well-known chemical with extensive prior art and broad industrial production.

IP category	Risk level for phenol
Composition-of-matter patent on phenol	Negligible
Basic manufacturing process patent	Low for commercial pharmaceutical use
Pharmaceutical-grade purification process	Low to moderate
Drug-specific preservative formulation	Moderate
Controlled-release or biologic formulation using phenol	Product-specific
Container or delivery-device patent	Product-specific
Supplier trade secret or process know-how	Moderate

The relevant patent risk is usually not ownership of phenol. It is whether a proposed generic or biosimilar product uses a protected formulation, preservative concentration, container system, or method of treatment.

When does phenol lose exclusivity in a drug product?

Phenol itself has no FDA exclusivity period because it is an excipient rather than a newly approved active pharmaceutical ingredient. Exclusivity attaches to the finished drug product, not to the presence of phenol.

Potential protections include:

• New chemical entity exclusivity for the active ingredient
• New clinical investigation exclusivity
• Orphan-drug exclusivity
• Pediatric exclusivity
• Patent protection listed in the Orange Book
• Biologic exclusivity under the Public Health Service Act
• Formulation and method-of-use patents

The presence of phenol does not extend an active ingredient’s patent term or regulatory exclusivity.

What is the Orange Book status of phenol?

Phenol is not an Orange Book-listed drug product in its role as an excipient. The Orange Book lists approved finished drug products and certain patent and exclusivity information, not a general patent estate for inactive ingredients (U.S. Food and Drug Administration, n.d.-b).

A generic applicant using phenol must assess the Orange Book patents for the reference listed drug. Those patents may cover:

• A preservative-containing formulation
• A specific concentration range
• A multidose container
• A method of stabilizing the active ingredient
• A method of treatment
• A combination of phenol with m-cresol or another excipient

How do Paragraph IV challenges affect phenol-containing medicines?

A Paragraph IV challenge concerns patents listed for an approved drug, not phenol itself. A generic applicant may certify that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed.

For a phenol-containing injectable, the main legal questions are:

1. Does the proposed generic use the same preservative system?
2. Does the patent claim a concentration range that covers the generic?
3. Does the patent require a specific container or vial format?
4. Can the generic use a different preservative without losing equivalence?
5. Does the patent claim a method of use rather than the formulation?

A generic applicant can sometimes avoid a formulation patent by using a different preservative or a different concentration. That approach creates technical and regulatory risk because the new formulation may require additional stability, sterility, compatibility, and bioequivalence support.

What biosimilar risk affects phenol demand?

Phenol does not create a direct biosimilar barrier. Biosimilar risk arises from competition against biologic products whose formulations may contain phenol, m-cresol, or another preservative.

Biosimilar developers may use:

• The same preservative system
• A different preservative
• A preservative-free single-dose presentation
• A different container closure
• A prefilled syringe or cartridge

If a biosimilar launches in a multidose format compatible with the reference product, phenol demand may remain stable while market share shifts between manufacturers. If the biosimilar uses single-dose packaging, phenol demand per treatment may decline.

For insulin and other protein products, preservative selection is technically sensitive because preservatives can affect protein structure, aggregation, adsorption, and injection-site tolerability. This limits rapid substitution.

What patent litigation and settlements affect phenol-containing products?

Public litigation generally focuses on the finished drug, not on phenol as an excipient. Relevant disputes can involve insulin, vaccine, peptide, and biologic products where phenol is part of the formulation.

Litigation risk can arise from:

• Formulation patents
• Device patents
• Manufacturing patents
• Stability claims
• Dosing or administration patents
• Method-of-treatment patents
• Patent-term-extension calculations

Settlement agreements may delay generic or biosimilar entry even when the underlying phenol supply remains available. The commercial exposure belongs to the finished-product owner and supplier network, not to phenol as a standalone chemical.

What geographic factors affect phenol pharmaceutical supply?

Regional supply risk differs because production is concentrated in major petrochemical hubs.

North America

The region benefits from integrated petrochemical infrastructure and established FDA-regulated drug manufacturing. Supply interruptions can still affect customers that rely on a single qualified source.

Europe

European buyers face tighter chemical-safety, environmental, and worker-exposure requirements. REACH registration and classification obligations affect handling and documentation. European pharmacopeial compliance is important for suppliers selling into EU-regulated products (European Chemicals Agency, n.d.).

Asia-Pacific

Asia-Pacific has major phenol production capacity and a large pharmaceutical manufacturing base. Buyers may obtain cost advantages but must assess supplier auditability, transport controls, change-notification practices, and continuity planning.

Emerging markets

Local manufacturing growth may increase phenol demand for vaccines, injectables, and generic insulin. Regulatory fragmentation and lower-cost procurement can increase qualification complexity.

What is the financial trajectory for pharmaceutical-grade phenol?

The expected trajectory is stable to modestly growing in volume, with pricing driven by the industrial phenol cycle rather than pharmaceutical innovation.

Period	Expected market condition	Financial implication
Near term	Volatile feedstock and energy costs	Pricing remains exposed to petrochemicals
Medium term	Stable demand from legacy injectables and vaccines	Volume growth remains limited
Longer term	More preservative-free and single-dose products	Downward pressure on demand intensity
Across the cycle	Qualification and supply assurance remain valuable	Premiums persist for validated grades

Revenue exposure for a phenol supplier depends on the customer mix:

• Bulk industrial customers create volume but lower margins.
• Pharmaceutical customers generate smaller volumes but higher documentation and qualification value.
• Contract and catalog channels can support higher unit pricing.
• A single large insulin or vaccine customer can create material concentration risk.

The strongest financial position belongs to suppliers with integrated production, pharmaceutical-grade purification, multiple qualified sites, long-term contracts, and documented change-control systems.

How strong is the patent and commercial position for phenol?

Phenol has low patent strength but strong operational defensibility.

Patent strength

The molecule is effectively commoditized. New composition patents are not a realistic source of protection. Process patents may protect efficiency or purity improvements, but they are unlikely to block ordinary pharmaceutical sourcing.

Commercial strength

Commercial defensibility is higher because pharmaceutical customers require:

• Approved supplier status
• Consistent impurity profiles
• Audited quality systems
• Validated packaging
• Regulatory support
• Change-control notifications
• Reliable hazardous-material logistics

This creates switching costs even when multiple chemical suppliers exist.

What generic launch scenarios exist for phenol-containing drugs?

Three launch scenarios are most relevant.

Same-formulation generic

The generic uses phenol at a comparable level and in a similar container. This may reduce technical risk but can increase exposure to formulation patents.

Alternative-preservative generic

The generic replaces phenol with m-cresol or another system. This may avoid a patent claim but requires extensive compatibility and stability evidence.

Preservative-free generic

The generic uses a single-dose vial, cartridge, syringe, or other presentation. This can reduce preservative exposure but may increase packaging, fill-finish, and manufacturing costs.

The commercial outcome depends on whether the product competes primarily on price, convenience, storage, device integration, or preservative profile.

Key Takeaways

• Phenol is an established pharmaceutical preservative, especially in multidose injectables, insulin products, and selected vaccines.
• Pharmaceutical-grade phenol is a small niche within a much larger industrial phenol market.
• Standalone market-size and revenue data are limited because suppliers report phenol by broad industrial segments.
• Phenol has no meaningful composition-of-matter patent estate.
• Orange Book and Paragraph IV risk attach to finished drug formulations, not to phenol itself.
• Biosimilar competition may reduce phenol demand when competitors use preservative-free or single-dose presentations.
• The main commercial moat is supplier qualification, quality consistency, documentation, and continuity of supply.
• Demand should remain stable in the near term but may decline gradually on a per-dose basis as single-dose and preservative-free products expand.
• Pricing will continue to track benzene, propylene, acetone, energy, freight, and regional phenol capacity.
• The highest-value suppliers are integrated producers that can support pharmaceutical-grade specifications and multi-region supply.

FAQs

Is phenol the same as m-cresol in insulin formulations?

No. Phenol and m-cresol are different chemical preservatives. Some insulin products use one, while others use both.

Can a pharmaceutical manufacturer freely substitute m-cresol for phenol?

No. Substitution can change antimicrobial performance, protein stability, local tolerability, container compatibility, and regulatory status.

Does phenol require a Drug Master File for pharmaceutical use?

A supplier may use a Drug Master File or equivalent regulatory package, but the requirement depends on the customer, product, jurisdiction, and regulatory strategy.

Is pharmaceutical-grade phenol more expensive than industrial phenol?

Usually, yes. The premium reflects purification, testing, packaging, documentation, audit requirements, and validated supply controls rather than the intrinsic value of the molecule.

Can phenol shortages stop insulin or vaccine production?

They can create a supply risk where phenol is a critical formulation component and no qualified alternative supplier or formulation exists. The risk is product-specific and depends on inventory, dual sourcing, and regulatory flexibility.

References

1. European Chemicals Agency. (n.d.). Phenol: Substance information. https://echa.europa.eu/

2. U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (n.d.-c). Pneumovax 23 prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

5. U.S. Food and Drug Administration. (n.d.-d). Typhim Vi prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

6. U.S. Food and Drug Administration. (n.d.-e). Humalog prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

7. U.S. Food and Drug Administration. (n.d.-f). NovoLog prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

8. United States Pharmacopeia. (n.d.). Phenol monograph. USP-NF. https://www.usp.org/npnf